

Challenges in Glycemic Monitoring: Undetectable HbA1c Level in an Asymptomatic Patient with Hemoglobin E and Beta-Thalassemia Minor: A Case Report

Dita Prawitasari,^{1,2,3} Syaifuddin Zuhri,^{1,2,3} Robiul Fuadi^{2,4}

¹Clinical Pathology Specialist Education Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

²Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

³Department of Clinical Pathology, Dr. Soetomo General Hospital, Surabaya, Indonesia

⁴Department of Clinical Pathology, Airlangga University Hospital, Surabaya, Indonesia

Abstract

Glycated hemoglobin (HbA1c) is a laboratory examination recommended by the American Diabetes Association to monitor blood glucose levels in patients with diabetes mellitus. This gold standard method for testing HbA1c uses high-performance liquid chromatography (HPLC). One advantage of HbA1c testing with HPLC is the ability to detect Hb variants or hemoglobinopathies, although HbA1c results may become irrelevant in such conditions. A 49-year-old female patient came to the Ophthalmology Outpatient Clinic of Dr. Soetomo Hospital due to visual impairment in both eyes and plans for cryotherapy surgery. In preparation for the surgery, laboratory tests were performed with results of haemoglobin 12.1 g/dL, mean corpuscular volume 58.9 fL, mean corpuscular haemoglobin 19.3 pg, leukocytes 13,370/uL, platelets 399,000/uL and random blood glucose 127 mg/dL; however, HbA1c was not detected. In the HbA1c test, a 93.7% window variant was obtained. Based on blood smear evaluation, there was hypochromic microcytic anisopoikilocytosis with target cells. The electrophoresis results revealed HbA 0.7%, HbF 0.6%, HbE 94.9% and HbA2 4.7%, indicating the presence of beta thalassemia with hemoglobinopathy E. The diagnosis of hemoglobinopathy E is based on a complete blood count, peripheral blood smear and haemoglobin electrophoresis. HbA1c examination by HPLC can yield undetectable HbA1c levels in hemoglobinopathies. Monitoring blood glucose levels in such cases is also irrelevant when using HbA1c, because red blood cells have a shorter lifespan in the presence of Hb variants. Glucose monitoring in this condition can be done by periodic glucose examination, fructosamine, or glycated albumin. The HbA1c test cannot be used as a marker of glucose control in patients with hemoglobinopathy E.

Key words: hemoglobinopathy, HbA1c, HPLC, electrophoresis

INTRODUCTION

Glycated hemoglobin or hemoglobin A1c (HbA1c) is a hemoglobin fraction commonly used to evaluate long-term glycemic control and the risk of chronic complications in patients with diabetes mellitus. The American Diabetes Association (ADA) recommends HbA1c as one of the diagnostic criteria related to diabetes mellitus because it can reflect glucose bound to hemoglobin throughout the life of the erythrocyte (approximately 120 days), so that it can indirectly reflect clinical changes related to glucose exposure during this period, although factors that can affect hemoglobin concentration or erythrocyte turnover can also influence it.¹

Several methods are known for HbA1c testing, including immunoassay, boronate affinity, enzymatic, capillary electrophoresis and ion-exchange high-performance liquid

chromatography (HPLC). The latter two methods offer additional advantages beyond measuring HbA1c, as they can also detect various hemoglobin types and Hb variants. HPLC testing itself is known to have high sensitivity and specificity and can be used as an alternative to electrophoresis in identifying and measuring normal and abnormal hemoglobin fractions. The retention time obtained from HPLC testing can provide information about hemoglobin variants in a sample, both in measuring HbA1c, HbA2, and HbF levels. This allows for monitoring therapy and the progression of diabetes mellitus, as well as detecting recessively inherited hemoglobinopathies such as thalassemia and hemoglobinopathy E.^{2,3}

Located in the thalassemia belt region, the prevalence of thalassemia carriers in Indonesia, according to WHO, is around 6-10% of the population, so it is estimated that there are 6-10 thalassemia carriers out of 100 residents.⁴

eISSN 2308-118x (Online)

Printed in the Philippines

Copyright © 2026 by Prawitasari et al.

Received: February 4, 2026. Accepted: March 8, 2026.

Published online first: August 10, 2026.

<https://doi.org/10.15605/jafes.041.02.6223>

Corresponding author: Robiul Fuadi, MD, PhD

Clinical Pathologist, Department of Clinical Pathology, Faculty of Medicine,

Universitas Airlangga; and Clinical Pathology Laboratory,

Universitas Airlangga Hospital, Prof. Dr. Moestopo No. 47,

Surabaya, East Java 60132, Indonesia

Tel. No. (+62) 31 5020251

E-mail: muhamad-r-u-fk@fk.unair.ac.id

ORCID: <https://orcid.org/0000-0002-8416-6862>

More specifically, local estimates indicate that approximately 3.0–10.0% of the Indonesian population carries the beta-thalassemia trait and 2.6–11.0% carry the alpha-thalassemia trait, with around 2,500 infants born with beta-thalassemia major each year.⁵ Hemoglobin E is also among the most common structural hemoglobin variants in Southeast Asia and is frequently co-inherited with beta-thalassemia.⁵ Importantly, Indonesia's national newborn screening program is currently mandated only for congenital hypothyroidism and does not include hemoglobinopathies; consequently, individuals with beta-thalassemia minor or hemoglobin E commonly remain undetected until incidental laboratory testing later in life.⁶ This makes hemoglobinopathy a condition that is not rarely encountered; however, due to the absence of significant clinical symptoms in sufferers, especially in carriers, the choice of examination method can be very decisive.

CASE

A 49-year-old woman presented to the Eye Clinic at Dr. Soetomo General Hospital complaining of impaired vision in both eyes. She was reported to have blurred vision in her right eye and undetectable vision in her left eye. The patient did not complain of eye pain, fever, or impaired eye movement. She had no history of malignancy or metabolic disease, but had a history of hypertension and had not been taking her medication regularly. A physical examination revealed decreased visual acuity in both eyes and a leuconia over the entire surface of the left cornea. The attending physician diagnosed the patient with phthisis bulbi and left corneal leuconia and planned cryotherapy (CRI).

Prior to the surgical procedure, routine laboratory testing revealed a random blood glucose level of 127 mg/dL (N: <200 mg/dL) and an undetectable HbA1c result. HbA1c measurement was performed using the Bio-Rad D-10 high-performance liquid chromatography (HPLC) system. The chromatogram showed no detectable HbA1c peak at the expected retention time of approximately 2.0 to 2.2 minutes, with an abnormal chromatographic disturbance observed near this region. No variant window was initially identified (Figure 1). Because of this unexpected finding, the sample was diluted and reanalyzed. The repeated chromatogram again demonstrated the absence of the HbA1c peak at the expected retention time, while a prominent variant window peak occupying 93.7% of the total chromatogram area became evident, indicating the presence of a hemoglobin variant (Figure 2).

Other laboratory findings from the complete blood count are summarized in Table 1, demonstrating hemoglobin 12.1 g/dL, hematocrit 36.9%, erythrocytes 6,270,000/uL, mean corpuscular volume (MCV) 58.9 fL, mean corpuscular hemoglobin (MCH) 19.3 pg, leukocytes 13,370/uL, and platelets 399,000/uL (Figure 3). Based on the complete blood count, the patient's Mentzer index was 9.4, suggesting a possibility of thalassemia, as the number




Figure 1. Pre-dilution HbA1c chromatogram using the Bio-Rad D-10 HPLC system. An undetectable HbA1c value is shown. The HbA1c peak, normally expected at a retention time of 0.79–1.01 seconds, was not identifiable in this chromatogram, likely due to masking by an extremely elevated hemoglobin variant that disrupted the normal elution pattern. The transverse line is visible, which may serve as an indirect diagnostic indicator of a high-concentration abnormal hemoglobin fraction. No variant window was detected.

of erythrocytes remained high despite a small size of the red blood cells. Peripheral blood smear examination was then carried out and revealed microcytic hypochromic erythrocytes with (+) target cells suspicious for thalassemia (Figure 4). Furthermore, electrophoresis was performed, and the results obtained were HbA 0.5% (N: 96.8–97.5%), HbF 0.6% (N: 0.0%), HbE 94.4% (N: not detected), HbA2 4.5% (N: 2.4–2.9%). Based on these results, a decrease in the HbA fraction and an increase in the HbF, HbE and HbA2 fractions were observed, suggesting beta thalassemia with hemoglobinopathy E (Figure 5).

Asymptomatic patients with no history of the disease in their family are advised to have a genetic consultation for screening for genetic disorders that may be transmitted through them to their offspring.




Figure 2. Post-dilution HbA1c chromatogram using the Bio-Rad D-10 HPLC system. An undetectable HbA1c value is still present after sample dilution. The HbA1c peak remains undetectable even sample dilution. The transverse line is still visible on the chromatogram, and a variant window is present with a total area of 93.7%, consistent with a highly elevated hemoglobin variant.

Parameter	Result	Unit	Reference range
Hemoglobin (Hb)	12.1	g/dL	Male: 13.3–16.6 Female: 11.0–14.7
Red Blood Cells (RBC)	6.27	$\times 10^9/\mu\text{L}$	3.69–5.46
Hematocrit (HCT)	36.9	%	Male: 41.3–52.1 Female: 35.2–46.7
Mean Corpuscular Volume (MCV)	58.9	fL	86.7–102.3
Mean Corpuscular Hemoglobin (MCH)	19.3	pg	27.1–32.4
Mean Corpuscular Hemoglobin Concentration (MCHC)	32.8	g/dL	29.7–33.1
RDW-SD	31.8	fL	41.2–53.6
RDW-CV	17.7	%	12.2–14.8
White Blood Cells (WBC)	13.37	$\times 10^3/\mu\text{L}$	3.37–10.0
Neutrophils	66.3	%	39.8–70.5
Lymphocytes	23.1	%	23.1–49.9
Monocytes	5.8	%	4.3–10.0
Eosinophils	4.4	%	0.6–5.4
Basophils	0.4	%	0.3–1.4
Platelets (PLT)	399	$\times 10^3/\mu\text{L}$	150–450
Mean Platelet Volume (MPV)	9.7	fL	9.2–12.0
Platelet Distribution Width (PDW)	11.7	fL	9.6–15.2
Plateletcrit (PCT)	0.39	%	0.19–0.39




Figure 3. Red blood cell (RBC) histogram showing a leftward shift consistent with microcytic red blood cells.




Figure 4. Examination of a peripheral blood smear with 1000x magnification showing the presence of target cells indicated by the blue arrows.

DISCUSSION

The diagnosis of hemoglobinopathy E is based on a complete blood count (CBC), specialized hematology tests, and DNA testing. A complete blood count (CBC) is the initial test commonly performed to screen for thalassemia or other hemoglobinopathies by assessing decreased MCV or MCH values, although iron deficiency anemia can also have similar symptoms. This means that the diagnosis of hemoglobinopathy cannot be based solely on MCV or MCH levels. It requires additional values, such as the MCV/RBC ratio or the Mentzer index, a peripheral blood smear, and other specialized tests such as HPLC (HbA1c) and electrophoresis, or, most effectively, DNA mutation analysis.⁷




Figure 5. Electrophoresis examination showing high HbE values.

The HbA1c is a routine test for monitoring long-term blood sugar levels in patients with diabetes mellitus because it directly correlates with the risk of complications from the condition. Because it relates to hemoglobin, the HbA1c test can be influenced by factors such as erythrocyte survival time and the levels of certain hemoglobin fractions.^{1,8} Because the HbA1c test is based on normal hemoglobin, the presence of other conditions such as hemoglobinopathies can affect the test results.⁹ This is evident in the patient's HbA1c test results, which are still undetectable on the device even after repeating the test with dilution.

The undetectable HbA1c levels on the HPLC method used in this patient may be due to changes in the glycation process from HbA to A1c, resulting in abnormal peaks that make the A1c estimate unreliable. Hemoglobinopathy itself can make red blood cell production more susceptible to hemolysis, shortening glycosylation time, resulting in falsely low or even undetectable A1c results.⁹ This is indicated by the appearance of transverse lines on two HbA1c test graphs, indicating this change (Figures 1 and 2).

Hemoglobinopathies are divided into two groups: thalassemia and hemoglobin variants.^{1,8} In this patient, a high variant-window area of 93.7% was observed, with a decrease in the HbA fraction and an increase in the HbF, HbE, and HbA2 fractions, suggesting beta thalassemia with hemoglobinopathy E on the second test, after sample dilution. HPLC is an examination that separates various types of hemoglobin on a cation-exchange column and usually requires only a single sample injection. This examination is usually used as an alternative to electrophoresis examination but has the ability to identify and quantitatively measure low levels of HbA2 and HbF, although co-migration between HbA2 and HbE can occur, so that inaccurate HbA2 levels can occur due to the presence of other hemoglobin variants such as HbE, Lepore, DPunjab and S.^{2,10}

The results of the HbA1c examination were then confirmed by the results of other laboratory tests, such as the patient's complete blood count, which showed a hemoglobin level of 12.1 g/dL, hematocrit 36.9%, erythrocytes 6,270,000/uL, MCV 58.9 fL, MCH 19.3 pg, leukocytes 13,370/uL, platelets 399,000/uL, and an increase in the RDW-CV value of 17.7%, indicating the possibility of variations in the shape of erythrocytes in the measured sample. Based on these results, a Mentzer index of less than 13 (9.4) indicated the possibility of the patient suffering from thalassemia. This is also supported by the peripheral blood smear, which showed hypochromic microcytic erythrocytes with target cells (+), suspicious for thalassemia. This result was further confirmed by electrophoresis, which showed a decrease in the HbA fraction, an increase in the HbF, HbE and HbA2 fractions, suggesting a beta thalassemia with hemoglobinopathy E. The uniqueness of this case is that the patient was asymptomatic, without a known family history, no signs of pancytopenia and no signs of hemolytic events or other complications, although this condition could possibly be caused by a variant form of the homozygous or heterozygous HbE trait, which often causes clinicians to miss the attention of their diabetic patients with inappropriate HbA1c results.¹¹⁻¹³ The HbE condition is a thalassemic hemoglobinopathy with an abnormal HbE structure due to spontaneous point mutations in the beta-globin chain, causing substitution of lysine for glutamic acid, and the disease pattern is similar to that of beta thalassemia.^{14,15}

In areas with high prevalence of Hb variants, clinical laboratory examinations need to consider various limitations of the examination, including those for HbA1c determination. The presence of other clinical conditions, such as hemoglobinopathies, can lead to silent conditions that make HbA1c levels determined by HPLC fail to reflect actual blood glucose levels, making treatment for diabetes patients becomes less appropriate.¹⁵⁻¹⁷ On the other hand, HbA1c examination with HPLC is preferred

over other methods, such as immunoturbidity or point-of-care tests, because it can detect Hb variants, both homozygous and heterozygous, which can make HbA1c results less accurate.¹⁷ Therefore, it is important to educate clinicians to avoid ordering HbA1c examinations in these patients. It is also worth noting that in regions within the thalassemia belt, such as Indonesia, hemoglobinopathy may remain undiagnosed well into adulthood in asymptomatic individuals.⁶ In many individuals with HbE trait or beta-thalassemia minor, clinical manifestations may be minimal and therefore remain undiagnosed unless routine laboratory testing is performed. In this case, the hemoglobinopathy was incidentally detected during preoperative laboratory evaluation. On the other hand, the subtle microcytic picture of HbE is frequently attributed to iron deficiency, and neither electrophoresis nor HPLC is performed routinely in primary care, in the absence of clinical suspicion or family history, underscoring the need for heightened clinical awareness. Patients with Hb variants who have diabetes mellitus should be advised to use other methods of glucose monitoring that are not based on hemoglobin, such as fructosamine, glycated albumin or periodic glucose examinations to determine long-term glycemic control.^{5,18-20}

CONCLUSION

Undetectable HbA1c values and the appearance of window variants on HPLC can be caused by hemoglobinopathies. This condition can be an initial indicator of Hb variants in patients with hemoglobinopathies or thalassemia traits who are clinically asymptomatic. Therefore, HbA1c testing cannot be used to monitor blood glucose levels in patients with hemoglobinopathies.

Acknowledgments

The authors would like to thank the medical and laboratory staff of the Department of Clinical Pathology, Dr. Soetomo General Hospital, and the Faculty of Medicine, Universitas Airlangga, Surabaya, for their invaluable assistance in patient evaluation, laboratory analysis, and data collection.

Ethical Consideration

Patient's consent was obtained before submission of the manuscript.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

CRedit Author Statement

DPS: Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing – original draft preparation, Visualization, Supervision, Project administration, Funding acquisition; **SZ:** Conceptualization, Methodology, Software, Formal analysis, Investigation, Resources, Data curation, Writing – review and editing, Visualization, Project administration, Funding acquisition; **MRF:** Methodology, Software, Validation, Formal analysis, Data curation, Writing – review and editing, Project administration, Funding acquisition.

Data Availability Statement

All data generated or analyzed during this study are included in this published article.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. American Diabetes Association. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. *Diabetes Care*. 2024;47(1):S20-42. DOI: 10.2337/dc24-S002
2. Keohane EM, Smith LJ, Walenga JM. Rodak's hematology clinical principles and applications, 5th ed. Elsevier; 2016. <https://labscientists.wordpress.com/wp-content/uploads/2019/04/rodaks-hematology-5e-2016-unitedvrg.pdf>
3. Khara R, Singh T, Khuana N, Gupta N, Dubey AP. HPLC in characterization of hemoglobin profile in thalassemia syndromes and hemoglobinopathies: A clinicohematological correlation. *Indian J Hematol Blood Transfus*. 2015;31(1):110-5. PMID: 25548455 PMCID: PMC4275515 DOI: 10.1007/s12288-014-0409-x
4. Kementerian Kesehatan Republik Indonesia. Putuskan Mata Rantai Talasemia, untuk Indonesia Lebih Sehat; 2019.
5. Wahidiyat PA, Sari TT, Rahmartani LD, et al. Thalassemia in Indonesia. *Hemoglobin*. 2022;46(1):39-44. PMID: 35950580 DOI: 10.1080/03630269.2021.2023565
6. Octavius GS, Daleni VA, Sagala YDS. An insight into Indonesia's progress for newborn screening program: What is currently going on. *Heliyon*. 2024;10(13):e33479. PMID: 39035496 PMCID: PMC11259875 DOI: 10.1016/j.heliyon.2024.e33479
7. Trent, RJA. Diagnosis of the haemoglobinopathies. *Clin Biochem Rev*. 2006;27(1):27-38. PMID: 16886045 PMCID: PMC1390791
8. Aktas A, Ipek BO, Dikler O. Unmeasurable HbA1c result due to hemoglobinopathy. *Int J Med Biochem*. 2024;7(1):41-4. DOI: 10.14744/ijmb.2023.59480
9. Smaldone A. Glycemic control and hemoglobinopathy: When A1c may not be reliable. *Diabetes Spectrum*. 2008;21(1):46-9. DOI: 10.2337/diaspect.21.1.46
10. Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Haematology, 12th ed. Elsevier; 2016.
11. Bhattarai U, Adhikari D, Gautam A, Anand A, Shah B, Sharma SK. Severe homozygous HbE disease: The first case report from Nepal. *Oxf Med Case Reports*. 2023;2023(6):omad062. PMID: 37377720 PMCID: PMC10292636 DOI: 10.1093/omcr/omad062
12. Basumatary N, Baruah D, Sarma PK, Sarma J. A case report of co-occurrence of hemoglobinopathy EE and glucose-6-phosphate dehydrogenase A+ variant. *Biomed Biotechnol Res J*. 2023;7(4):646-8. DOI: 10.4103/bbrj.bbrj_228_23
13. Yedla N, et al. Hemoglobin E disease and glycosylated hemoglobin. *Indian J Endocrinol Metab*. 2015;19(5):683-5. PMID: 26425484 PMCID: PMC4566355 DOI: 10.4103/2230-8210.163211
14. Sri VLP, Sreeja C, Muthukumar RS, Nachiamma N, Jayaraj M, Priya AHH. HBE homozygous haemoglobinopathy – Fortuitous finding. *J Oral Maxillofac Pathol*. 2022;26(4):580-2. PMID: 37082065 PMCID: PMC10112082 DOI: 10.4103/jomfp.jomfp_98_22
15. Gargallo MA, González FA, Villegas A. Abnormally low HbA1c secondary to hemoglobin J-Baltimore [beta 16(A13) Gly→Asp]. Family study. *Endocrinol Nutr*. 2010;57(2):83-5. PMID: 20206586 DOI: 10.1016/j.endonu.2010.01.004
16. Mitchai M, Suwansaksri N, Seanseeha S, et al. Misleading HbA1c measurement in diabetic patients with hemoglobin variants. *Med Sci (Basel)*. 2021;9(2):43. PMID: 34200315 PMCID: PMC8293317 DOI: 10.3390/medsci9020043
17. Dupuy AM, Cristol JP, Bargnoux AS, et al. The pivotal role of HbA1c assay to detect hemoglobinopathies: A 5-year observational retrospective study in the population of Southern France. *Health Sci Rep*. 2023;6(7):e1270. PMID: 37465239 PMCID: PMC10350560 DOI: 10.1002/hsr2.1270
18. Chung K, Huang N. Undetectable glycated hemoglobin (HbA1c): An interesting case. *Clin Diabetol*. 2023;12(2):135-6. DOI: 10.5603/DK.a2023.0004
19. Hegde SN, Srikousthubha MS, Anupama YJ. A case of undetectable glycated hemoglobin (HbA1c). *QJM*. 2018;111(8):567-8. PMID: 29660089 DOI: 10.1093/qjmed/hcy080
20. Liddy AM, Grundy S, Sreenan S, Tormey W. Impact of hemoglobin variants on use of the haemoglobin A1c for the diagnosis and monitoring of diabetes: A contextualised review. *Ir J Med Sci*. 2022; 192(1):169-76. PMID: 35362846 PMCID: PMC9892076 DOI: 10.1007/s11845-022-02967-2

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights; that no references have been made to predatory/suspected predatory journals; and that use of artificial intelligence (AI) or AI-assisted technologies shall be declared to include the name of the AI tool or service used; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (*optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.



Experience the new JAFES.
Visit us at www.ASEAN-endocrinejournal.org.